10-Q: Corcept Q3 2025: Revenue Up, Profit Down Amid R&D Push

Corcept Therapeutics reported increased product revenue for Q3 and the nine months ended September 30, 2025, driven by higher sales volume, but net income declined due to significantly increased operating expenses and R&D investments.

Summary

• Product revenue increased to $207.6 million for the three months ended September 30, 2025, up from $182.5 million in the comparable 2024 period, and to $559.3 million for the nine months, up from $493.2 million.
• Sales volume increased by 42.5% for the three months and 39.0% for the nine months, partially offset by average price decreases of 20.2% and 18.4% due to the authorized generic version of Korlym.
• Net income decreased to $19.7 million for the three months ended September 30, 2025, from $47.2 million in the prior year, and to $75.4 million for the nine months, from $110.5 million.
• Diluted net income per common share decreased to $0.16 for the three months and $0.62 for the nine months ended September 30, 2025, compared to $0.41 and $0.98, respectively, in the prior year.
• Operating expenses significantly increased, with selling, general and administrative expenses rising to $318.5 million for the nine months (from $196.9 million in 2024) and research and development expenses increasing to $190.1 million (from $176.6 million in 2024).
• The company recorded an income tax benefit of $18.8 million for the nine months ended September 30, 2025, compared to an expense of $19.1 million in the prior year, primarily due to increased stock compensation deductions, decreased pre-tax income, and the enactment of the 'One Big Beautiful Bill Act'.
• Cash, cash equivalents, and marketable securities totaled $524.2 million as of September 30, 2025, a decrease from $603.2 million at December 31, 2024.
• $172.9 million was spent on common stock repurchases under the Stock Repurchase Program during the nine months ended September 30, 2025, with $11.4 million of authorization remaining.

Sentiment

Score: 5

Explanation: While revenue growth is positive and the pipeline shows promising clinical trial results and regulatory progress for relacorilant, the significant decline in net income and operating income, coupled with increased operating expenses and ongoing legal challenges, creates a mixed financial picture. The ALS trial failing its primary endpoint is a setback, though the survival benefit is a positive. The overall sentiment is neutral to slightly cautious due to financial performance despite pipeline advancements.

Positives

• Product revenue increased by 13.75% for the three months and 13.40% for the nine months ended September 30, 2025, driven by significant sales volume growth.
• The CATALYST study for hypercortisolism in difficult-to-control diabetes met its primary endpoint, showing a clinically meaningful and statistically significant decrease in HbA1c of 1.47% in patients receiving Korlym (p-value: < 0.0001).
• Relacorilant's New Drug Application (NDA) for hypercortisolism was accepted by the FDA with a PDUFA date of December 30, 2025, based on positive results from pivotal GRACE and confirmatory GRADIENT trials.
• Relacorilant's NDA for platinum-resistant ovarian cancer (in combination with nab-paclitaxel) was accepted by the FDA with a PDUFA date of July 11, 2026, following positive results from the pivotal ROSELLA trial (30% reduction in risk of disease progression, HR: 0.70; p-value: 0.008).
• An interim analysis of the ROSELLA trial showed a meaningful 31% reduction in risk of death (hazard ratio: 0.69; p-value: 0.012) with a median OS of 16.0 months compared to 11.5 months for nab-paclitaxel alone.
• Relacorilant has received Orphan Drug Designation from the FDA for hypercortisolism (7 years exclusive marketing) and from the EC for hypercortisolism, ovarian, and pancreatic cancers (10 years exclusive marketing in EU for hypercortisolism).
• Dazucorilant for ALS showed a statistically significant reduction in early death in an exploratory analysis of the DAZALS Phase 2 trial, with a 300 mg dose showing an 84% reduction in risk of death compared to placebo (hazard ratio: 0.16; p-value: 0.0009).
• Dazucorilant has FDA Fast Track Designation and orphan drug status for ALS.
• The company expects to fund its operations and planned research and development activities for the next 12 months and beyond without needing to raise additional funds.
• The 'One Big Beautiful Bill Act' enacted on July 4, 2025, allowed for immediate expensing of domestic R&D expenses, contributing to an income tax benefit.

Negatives

• Net income significantly decreased by 58.3% for the three months and 31.8% for the nine months ended September 30, 2025, compared to the prior year.
• Diluted net income per common share decreased by 60.9% for the three months and 36.7% for the nine months ended September 30, 2025.
• Income from operations decreased substantially to $40.3 million for the nine months ended September 30, 2025, from $111.7 million in the comparable 2024 period.
• Selling, general and administrative expenses increased by 61.7% for the nine months ended September 30, 2025, reflecting higher commercial and administrative activities.
• Research and development expenses increased by 7.6% for the nine months ended September 30, 2025, indicating continued high investment in pipeline.
• Cash, cash equivalents, and marketable securities decreased by $79.0 million from December 31, 2024, to September 30, 2025.
• Net cash provided by operating activities decreased by $34.7 million for the nine months ended September 30, 2025, compared to the prior year.
• Net cash used in financing activities increased significantly to $189.2 million for the nine months ended September 30, 2025, primarily due to increased stock repurchases.
• The DAZALS Phase 2 trial for dazucorilant in ALS did not meet its primary endpoint (change from baseline in ALS Functional Rating Scale-Revised).
• The District Court ruled that Teva's proposed generic Korlym would not infringe Corcept's patents, leading to Teva's launch of a generic product in January 2024, which could materially harm revenue. Corcept's appeal is pending.
• The comparison between relacorilant and placebo in the GRADIENT study for systolic blood pressure was not statistically significant.

Risks

• Failure to generate sufficient revenue from the sale of products would harm financial results and stock price.
• The availability of generic versions of Korlym (Teva, Sun, Hikma) could adversely affect business, results of operations, and financial position.
• Public perception of mifepristone or legislation limiting or barring its distribution or use for termination of early pregnancy may limit the ability to sell current products.
• New laws, government regulations, or changes to existing laws and regulations (e.g., Inflation Reduction Act of 2022, One Big Beautiful Bill Act of 2025) could make it difficult to obtain acceptable prices or adequate insurance coverage and reimbursement for products, adversely affecting results.
• Vendors' failure to perform duties or meet timelines in clinical trials may prevent or delay product candidate approval.
• Clinical drug development is lengthy, expensive, and often unsuccessful; results of early studies are often not predictive of later trial results.
• Inability to secure, maintain, or effectively assert patent protection for proprietary compounds and methods of use; litigation is slow, expensive, and its outcome is uncertain.
• The price of common stock fluctuates widely and opportunities for investors to sell shares may be limited.
• Stock price may decline if performance does not meet public guidance, analyst estimates, or investor expectations.
• Actions by the federal government of the United States have created unprecedented legal, governmental, regulatory, and economic uncertainty and risks that may adversely affect business.
• Reliance on information technology; a breakdown or breach of IT systems could interrupt business and subject the company to liability.
• Products and product candidates may cause undesirable side effects that halt clinical development, prevent regulatory approval, limit commercial potential, or cause significant liability.
• The company may need additional capital to fund operations or for strategic reasons, which may not be available on acceptable terms or at all.
• Short-selling strategies may drive down the market price of common stock and increase its volatility.
• The company needs to increase the size of its organization and may experience difficulties in managing growth.
• Loss of key personnel or inability to attract skilled personnel.
• The company is subject to complex and costly regulations and legal obligations relating to drug development, commercialization, publicly traded securities, and individual privacy/data protection.
• Changes in federal, state, and local tax laws may reduce net earnings.
• Any acquisition of Corcept shares through the stock repurchase program or cashless option exercises will reduce cash reserves.
• Anti-takeover provisions in charter and bylaws and under Delaware law may make an acquisition or management change more expensive or difficult.
• Officers, directors, and principal stockholders, acting as a group, could significantly influence corporate actions.

Future Outlook

The company expects research and development expenses and selling, general and administrative expenses to be higher in 2025 than in 2024 due to the advancement of clinical programs, initiation of new clinical trials, and increased commercial and administrative activities to support increased sales and marketing efforts. The company anticipates the Inflation Reduction Act of 2022 will limit revenue from Medicare patients and may materially reduce profits in 2026 and beyond. The 'One Big Beautiful Bill Act' enacted in July 2025 is expected to materially reduce current income taxes payable and deferred tax asset balances due to the election to expense domestic research costs for tax purposes starting in 2025. The company expects to fund its operations and planned research and development activities over the next 12 months and beyond without needing to raise additional funds.

Management Comments

• Operating results for the threeand nine-month periods ended September 30, 2025 are not necessarily indicative of the results for the remainder of 2025 or any other period.
• Our policy is that no patient with hypercortisolism will be denied access to our Products for financial reasons.
• We expect our research and development expense to be higher in 2025 than in 2024 as our clinical programs advance and we initiate new clinical trials.
• Research and development spending in future years will depend on the outcome of our pre-clinical and clinical trials and our development plans.
• We expect our selling, general and administrative expense to be higher in 2025 than in 2024 due to increased commercial and administrative activities to support our increased sales and marketing efforts.
• Based on our current plans and expectations, we expect to fund our operations and planned research and development activities over the next 12 months and beyond without needing to raise additional funds, although we may choose to raise additional funds for other reasons.
• Although the outcome of any such matters and the amount, if any, of our liability with respect to them cannot be predicted with certainty, we do not believe that they will have a material adverse effect on our business, results of operations or financial position.
• The NJ USAO has informed us that it is investigating whether any criminal or civil violations by us occurred in connection with the matters referenced in the subpoena. It has also informed us that it does not currently consider us a defendant but rather an entity whose conduct is within the scope of the governments investigation.

Industry Context

The biopharmaceutical industry continues to face increasing regulatory scrutiny, particularly regarding drug pricing and patient assistance programs, as evidenced by the Inflation Reduction Act of 2022 and the 'One Big Beautiful Bill Act' of 2025, which are expected to impact revenue and profits. The legal landscape for intellectual property and antitrust remains challenging, with ongoing patent litigation against generic manufacturers and new antitrust lawsuits. Despite these pressures, the company is actively advancing a diverse pipeline of selective cortisol modulators for endocrinologic, oncologic, metabolic, and neurologic disorders, including orphan drug designations for key candidates, reflecting a strategic focus on high-unmet-need areas. The company's investment in R&D and sales/marketing aligns with industry trends of continuous innovation and aggressive commercialization for new product launches.

Comparison to Industry Standards

• The company's CATALYST study results for Korlym in difficult-to-control diabetes (1.47% HbA1c reduction) were published in Diabetes Care, the peer-reviewed journal of the American Diabetes Association, indicating recognition within the diabetes research community.
• Relacorilant's ROSELLA trial results for platinum-resistant ovarian cancer (30% reduction in risk of disease progression, 31% reduction in risk of death) were published in The Lancet, a highly respected medical journal, suggesting significant clinical impact compared to existing treatments.
• The Phase 2 trial results for relacorilant in platinum-resistant ovarian cancer were published in the Journal of Clinical Oncology, the premiere journal of the American Society of Clinical Oncology, further validating the findings.
• Relacorilant's safety profile, notably the absence of hypokalemia, endometrial hypertrophy, drug-induced vaginal bleeding, adrenal insufficiency, or QT prolongation, differentiates it from Korlym and other hypercortisolism treatments, which often carry such risks (e.g., Korlym's pivotal trial showed 44% of patients experienced hypokalemia).
• The company's strategy of developing selective cortisol modulators for various disorders (Cushing's, oncology, ALS, MASH) positions it in a niche but competitive market, with several other companies offering medications for hypercortisolism (e.g., Recordati-S.p.A. with pasireotide and osilodrostat, Xeris Biopharma Holdings, Inc. with levoketoconazole).

Legal Proceedings

• Teva Patent Litigation: The District Court ruled on December 29, 2023, that Teva's proposed generic product would not infringe Corcept's patents. Corcept has appealed this ruling to the United States Court of Appeals for the Federal Circuit, with oral argument held on July 7, 2025. Teva launched its generic product in January 2024.
• Teva Antitrust Litigation: Teva filed a complaint on June 13, 2024, alleging federal and state antitrust and unfair business practices against Corcept and Optime Care, Inc. The District Court granted in part and denied in part defendants' motion to dismiss on September 12, 2025. The case is scheduled for trial in January 2027.
• Aetna Litigation: Several named plaintiffs filed a complaint against Corcept on February 10, 2025, with allegations substantially similar to the Teva Antitrust Litigation. The case was remanded back to state court on September 18, 2025.
• Melucci Litigation: A securities class action complaint filed in March 2019 was settled in 2024 for a one-time payment of $14.0 million, which was fully reimbursed by insurers. This matter is closed.
• Shareholder Derivative Complaints (Williams, Jeweltex, Ritchie): Multiple shareholder derivative complaints were filed, consolidated, and subsequently dismissed. The Ritchie complaint was dismissed on July 22, 2025, and the Williams and Jeweltex complaints were dismissed on October 30, 2025.
• Records Subpoena: Received a subpoena from the United States Attorney's Office for the District of New Jersey in November 2021, seeking information related to the sale and promotion of Korlym, relationships with healthcare professionals, and prior authorizations/reimbursement. The company is cooperating with the investigation and is not currently considered a defendant.

Stakeholder Impact

• Shareholders: Potential for stock price volatility due to financial performance, clinical trial outcomes, regulatory decisions, and ongoing legal proceedings (patent and antitrust). The stock repurchase program aims to return value but reduces cash reserves.
• Patients: Continued access to Korlym and its authorized generic for hypercortisolism. Potential for new treatment options with relacorilant for hypercortisolism and platinum-resistant ovarian cancer, and dazucorilant for ALS, if approved. Patient support programs aim to ensure financial access to products.
• Employees: Increased employee compensation expenses and growth in commercial and administrative personnel indicate expansion. Stock-based compensation is a significant component.
• Customers (Physicians/Payors): Introduction of an authorized generic and potential new products (relacorilant) could offer more treatment options. However, government regulations (IRA, OBBBA) and increased scrutiny on pricing and patient assistance programs could impact reimbursement and access.
• Suppliers/Vendors: Continued reliance on third-party vendors for manufacturing, clinical trials, and distribution, with risks associated with their performance and compliance.
• Creditors: The company's strong cash position and expectation to fund operations without additional capital raises suggest a stable financial standing for creditors, though declining net income could be a concern if trends continue.

Next Steps

• FDA PDUFA date for relacorilant for endogenous hypercortisolism on December 30, 2025.
• Initiate a Phase 2 trial in 50 patients with pancreatic cancer by early next year.
• Initiate a Phase 2 trial in 50 patients with cervical cancer by early next year (collaborators ARCAGY-GINECO).
• Initiate a Phase 1b dose finding trial in 30 patients with solid tumors to evaluate nenocorilant plus nivolumab by early next year.
• Plan to start a pivotal Phase 3 trial of dazucorilant as a treatment for patients with ALS in 2026.
• FDA PDUFA date for relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer on July 11, 2026.
• Likely regulatory decision date for relacorilant MAA in EU for platinum-resistant ovarian cancer in the fourth quarter of 2026.
• Teva Antitrust Litigation scheduled for trial in January 2027.
• Plan to adopt ASU No. 2024-03 for the fiscal year ending December 31, 2027.
• Plan to adopt ASU No. 2025-06 for the fiscal year ending December 31, 2028.
• Continue to evaluate the effects of ASU No. 2024-03 and ASU No. 2025-06 on condensed consolidated financial statements.
• Continue to monitor and respond to the NJ USAO investigation.
• Vigorously enforce intellectual property rights relating to Korlym, including the appeal of the District Court's ruling in the Teva patent litigation.

Key Dates

Recommendation

While Corcept Therapeutics shows strong revenue growth driven by volume and has a promising pipeline with multiple NDAs under review and positive clinical trial results for relacorilant in hypercortisolism and ovarian cancer, the significant decline in net income and operating profit is a concern. The ongoing legal challenges, particularly the adverse ruling in the Teva patent litigation and the antitrust lawsuits, introduce substantial uncertainty and potential financial impact. The mixed results for dazucorilant in ALS (missed primary endpoint but showed survival benefit) add complexity. Given the strong pipeline potential balanced against the current financial performance decline and legal headwinds, a 'hold' recommendation is appropriate. Investors should monitor the PDUFA dates for relacorilant, the outcome of the Teva patent appeal, and the progress of the antitrust litigation.

Keywords

Corcept Therapeutics, Cushing's syndrome, Hypercortisolism, Korlym, Relacorilant, Ovarian cancer, Platinum-resistant ovarian cancer, Nab-paclitaxel, Dazucorilant, ALS, Amyotrophic Lateral Sclerosis, Miricorilant, MASH, Biopharmaceutical, Drug development, Clinical trials, FDA approval, Orphan drug, SEC filing, 10-Q, Financial results, Stock repurchase, Patent litigation, Antitrust litigation